MX2021013296A - Politerapia para tratar enfermedades artriticas. - Google Patents

Politerapia para tratar enfermedades artriticas.

Info

Publication number
MX2021013296A
MX2021013296A MX2021013296A MX2021013296A MX2021013296A MX 2021013296 A MX2021013296 A MX 2021013296A MX 2021013296 A MX2021013296 A MX 2021013296A MX 2021013296 A MX2021013296 A MX 2021013296A MX 2021013296 A MX2021013296 A MX 2021013296A
Authority
MX
Mexico
Prior art keywords
polytherapy
arthritic diseases
treat arthritic
treat
diseases
Prior art date
Application number
MX2021013296A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Engelbrecht Nordkild Jonassen
Original Assignee
Synact Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synact Pharma Aps filed Critical Synact Pharma Aps
Publication of MX2021013296A publication Critical patent/MX2021013296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013296A 2019-05-10 2020-05-07 Politerapia para tratar enfermedades artriticas. MX2021013296A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173734 2019-05-10
PCT/EP2020/062711 WO2020229297A1 (en) 2019-05-10 2020-05-07 Combination treatment of arthritic disease

Publications (1)

Publication Number Publication Date
MX2021013296A true MX2021013296A (es) 2021-12-15

Family

ID=66483881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013296A MX2021013296A (es) 2019-05-10 2020-05-07 Politerapia para tratar enfermedades artriticas.

Country Status (21)

Country Link
US (2) US12303489B2 (https=)
EP (2) EP3773558B1 (https=)
JP (1) JP7546599B2 (https=)
KR (1) KR20220006551A (https=)
CN (1) CN113795250B (https=)
AU (1) AU2020273479B2 (https=)
BR (1) BR112021022397A2 (https=)
CA (1) CA3139000A1 (https=)
CY (1) CY1125564T1 (https=)
DK (1) DK3773558T3 (https=)
ES (2) ES2927294T3 (https=)
HU (1) HUE059638T2 (https=)
IL (1) IL287904B2 (https=)
LT (1) LT3773558T (https=)
MX (1) MX2021013296A (https=)
PL (1) PL3773558T3 (https=)
PT (1) PT3773558T (https=)
SG (1) SG11202111821SA (https=)
SI (1) SI3773558T1 (https=)
WO (1) WO2020229297A1 (https=)
ZA (1) ZA202108219B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3773558T (lt) 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
CN120617247A (zh) * 2020-03-31 2025-09-12 西奈克制药有限公司 症状性病毒性疾病的治疗
WO2022223778A1 (en) 2021-04-23 2022-10-27 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament
EP4359076B1 (en) 2021-06-21 2025-08-06 SynAct Pharma ApS Phenyl pyrrole aminoguanidine salts and formulations
US20250032449A1 (en) * 2021-11-29 2025-01-30 Synact Pharma Aps Treatment of rheumatoid arthritis
WO2023218048A1 (en) * 2022-05-12 2023-11-16 Synact Pharma Aps Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
CN120584099A (zh) * 2022-12-21 2025-09-02 西奈克制药有限公司 苯基吡咯肼甲脒化合物的多晶型物
WO2025124760A1 (en) 2023-12-11 2025-06-19 Synact Pharma Aps Treatment of subpopulation of patients with rheumatoid arthritis
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604348D0 (sv) 1996-11-26 1996-11-26 Wapharm Ab Användning av hydroxyguanidiner
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001005401A1 (en) 1999-07-16 2001-01-25 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
WO2001055106A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
KR100440370B1 (ko) 2000-04-01 2004-07-19 (주)명문엘씨 2중 사출에 의한 밀폐용기 뚜껑
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
EP1370211A4 (en) 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
CA2363528A1 (en) 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
GB2398299A (en) 2003-02-13 2004-08-18 Melacure Therapeutics Ab Pharmaceutically active phenyl-pyrrole derivatives
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
NZ573457A (en) * 2006-06-09 2011-06-30 Action Pharma As Phenyl pyrrole aminoguanidine derivatives
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
EP2045250A1 (en) 2007-09-26 2009-04-08 Action Pharma A/S Ring-substituted phenyl pyrrole aminoguanidine derivatives
WO2009071101A1 (en) 2007-12-07 2009-06-11 Action Pharma A/S N-modified aminoguanidine derivatives
WO2009074157A1 (en) 2007-12-13 2009-06-18 Action Pharma A/S Fully-modified phenyl pyrrole aminoguanidines
US10387927B2 (en) 2010-01-15 2019-08-20 Dell Products L.P. System and method for entitling digital assets
JP2011190199A (ja) * 2010-03-12 2011-09-29 Hideto Nakamura 関節リウマチ薬
US9662807B2 (en) 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
US9917808B2 (en) 2013-03-14 2018-03-13 International Business Machines Corporation Grouping electronic messages
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
CN112292125B (zh) 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗
WO2020107221A1 (en) 2018-11-27 2020-06-04 Tsinghua University Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof
LT3773558T (lt) 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
CN113730797B (zh) 2020-05-29 2023-05-16 创领心律管理医疗器械（上海）有限公司 电极板及可穿戴式除颤设备

Also Published As

Publication number Publication date
US20220211666A1 (en) 2022-07-07
LT3773558T (lt) 2022-09-12
IL287904A (en) 2022-01-01
US12303489B2 (en) 2025-05-20
CN113795250B (zh) 2024-10-15
KR20220006551A (ko) 2022-01-17
JP2022531906A (ja) 2022-07-12
ES3041907T3 (en) 2025-11-17
PT3773558T (pt) 2022-09-13
CY1125564T1 (el) 2026-02-25
EP3773558A1 (en) 2021-02-17
EP4119140A1 (en) 2023-01-18
US20250387365A1 (en) 2025-12-25
ES2927294T3 (es) 2022-11-04
IL287904B2 (en) 2026-03-01
SI3773558T1 (sl) 2022-11-30
AU2020273479A1 (en) 2021-12-23
DK3773558T3 (da) 2022-09-19
EP4119140C0 (en) 2025-06-25
EP4119140B1 (en) 2025-06-25
IL287904B1 (en) 2025-11-01
WO2020229297A1 (en) 2020-11-19
PL3773558T3 (pl) 2022-10-03
JP7546599B2 (ja) 2024-09-06
HUE059638T2 (hu) 2022-12-28
CA3139000A1 (en) 2020-11-19
SG11202111821SA (en) 2021-11-29
ZA202108219B (en) 2023-03-29
EP3773558B1 (en) 2022-06-15
AU2020273479B2 (en) 2025-02-27
CN113795250A (zh) 2021-12-14
BR112021022397A2 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
MX2021013296A (es) Politerapia para tratar enfermedades artriticas.
CO2021003036A2 (es) Compuestos de anillo fusionado
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CL2019001293A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
CL2021001171A1 (es) Compuestos de anillo fusionado.
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
MX2019011660A (es) Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
MX2018013413A (es) Compuestos inhibidores de egfr.
CU24498B1 (es) Anticuerpos de factor xi
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2020005417A2 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
JOP20200157A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
MX2022007626A (es) Combinaciones.
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso